Who should not take hormone therapy?
Hormone therapy suits most healthy women near menopause, but not everyone. Here are the conditions that rule it out, the ones that call for caution, and why low-dose vaginal therapy is often still an option.
Women with a history of breast cancer, unexplained vaginal bleeding, blood clots, stroke, or active liver disease generally should not take systemic hormone therapy. Most other healthy women near menopause are candidates. A licensed clinician reviews your full history, including a prior heart attack, before making an individualized decision.
Who should generally avoid systemic hormone therapy?
Certain histories make systemic estrogen — patches, gels, or tablets that circulate through the whole body — inappropriate for most women. These are not arbitrary rules; they reflect conditions where added estrogen could worsen disease or raise serious risk. A clinician reviews your full personal and family history before prescribing, and these are the situations that typically rule systemic therapy out.
- A current or past history of breast cancer or other estrogen-sensitive cancer.
- Unexplained or abnormal vaginal bleeding that has not yet been evaluated.
- A history of blood clots in the legs or lungs (deep vein thrombosis or pulmonary embolism), or a known clotting disorder.
- A prior stroke, heart attack, or established cardiovascular disease.
- Active liver disease.
- Known or suspected pregnancy.
Contraindications to systemic hormone therapy include a history of breast or other estrogen-dependent cancer, prior venous thromboembolism or stroke, active liver disease, and unexplained vaginal bleeding.
Which conditions call for caution, not an automatic no?
Between clear candidates and clear contraindications sits a middle group: women for whom hormone therapy is not forbidden but requires careful weighing and often a specific approach. Here, the route and dose matter. For example, transdermal estradiol — a patch or gel — bypasses first-pass liver metabolism and appears to carry a lower clot risk than oral estrogen, which can make it the preferred choice when clot risk is a concern.
- A higher baseline risk of blood clots, where transdermal estradiol may be favored over oral.
- Migraine with aura, well-controlled high blood pressure, or elevated triglycerides.
- A strong family history of breast cancer, weighed individually with your clinician.
- Gallbladder disease, where the route of estrogen can influence risk.
| Category | Examples | Typical approach |
|---|---|---|
| Contraindicated | Breast cancer history, active liver disease, prior clot or stroke | Systemic estrogen generally avoided |
| Caution | High clot risk, migraine with aura, gallbladder disease | Individualized; transdermal often favored |
| Usually still an option | Genitourinary symptoms despite a systemic contraindication | Low-dose vaginal estradiol, minimal systemic absorption |
What about vaginal estrogen if I can't take systemic therapy?
Many women who should not use systemic hormone therapy can still safely treat the genitourinary syndrome of menopause — dryness, painful intimacy, and recurrent urinary symptoms — with low-dose vaginal estradiol. Because it acts locally with minimal systemic absorption, it is a different risk conversation entirely. The genitourinary syndrome of menopause affects up to half of postmenopausal women, and local therapy is often appropriate even when systemic estrogen is not, though women with a history of breast cancer should review this option with their oncology and menopause clinicians.
Low-dose vaginal estrogen has minimal systemic absorption and may be considered for genitourinary symptoms in many women who are not candidates for systemic therapy, individualized to each woman's history.
The bottom line
Hormone therapy has real benefits and real risks, and part of responsible care is being honest about who it does not suit. If you have one of the contraindications above, that does not mean nothing can help — non-hormonal options and, in many cases, low-dose vaginal therapy remain on the table. The right next step is a conversation with a licensed clinician who can match a plan to your specific history.
Questions, answered
Systemic hormone therapy is generally avoided in women with a history of breast or other estrogen-sensitive cancer, unexplained vaginal bleeding, prior blood clots or stroke, established heart disease, active liver disease, or known pregnancy. A licensed clinician reviews your full history, since the decision is individualized.
Explore the related treatments
If this is relevant to you, these are the treatments it most often connects to.
More from the blog
Non-hormonal options for menopause symptoms: what the evidence says
Hormone therapy is the most effective treatment for hot flashes, but it is not the only one. Here are the non-hormonal options with real evidence behind them — and how to tell them apart from the supplements that don't deliver.
8 min readMenopause and heart health: what changes and how to protect yourself
Heart disease is the leading cause of death in women, and risk shifts during menopause. Here is what changes, what the trials say about hormone therapy and the heart, and how to protect yourself.
8 min readPerimenopause symptoms: what age it starts and how long it lasts
What age does perimenopause start, and how long does it last? Here is the typical timeline and the full symptom list — for how perimenopause differs from menopause itself, see our companion guide.
7 min readFeel like yourself again.
Take the 3-minute assessment, then meet your clinician by video or phone. No obligation.